As biologics programs move closer to commercialization, timelines tighten and expectations for quality, regulatory readiness and scalability increase. Decisions made during development increasingly shape manufacturing performance, technology transfer and commercial readiness, making execution risk just as important as scientific progress.
Backed by deep expertise in process and analytical validation and process performance qualification, the Germany-based contract development and manufacturing organization (CDMO) reduces execution risk, improves timeline predictability and supports seamless progression from start to finish.
„Our clients are involved with our manufacturing team from the beginning. There are no translation errors, here are no surprises,“ says Thilo Kamphausen, Head of Business Development.
Richter BioLogics specializes in microbial process development, fermentation, purification, and GMP manufacturing. Process development, analytical strategy and manufacturing are aligned, ensuring every stage supports the next without disruption.
With nearly four decades of GMP manufacturing experience and recent investments in new GMP production lines, Richter BioLogics continues to strengthen its position as a trusted partner for biotechnology and pharmaceutical companies worldwide.
Building Integration from Day One
During a new microbial program, cross-functional teams engage simultaneously, whether developing a process from scratch or transferring an existing one for largescale manufacturing. Development scientists, analytical specialists and manufacturing teams work as a single project team from the outset, allowing decisions to be made with downstream manufacturing in mind. A dedicated project manager coordinates activities across departments, ensuring analytical strategies support process development milestones while maintaining a clear focus on GMP manufacturability.
This integrated approach reduces the risk of misalignment during technology transfer and manufacturing scale-up, creating continuity throughout development and production.
Connecting Fermentation and Purification
Microbial manufacturing demands precise coordination between upstream and downstream operations. Richter BioLogics has these activities designed as interconnected components of a unified manufacturing workflow.
It operates two independent multi-product GMP facilities, with upstream processing and downstream processing lines housed in separate suites. This decoupled setup provides clients with a high degree of process flexibility. Fermentation and purification activities are planned as an integrated workflow within a single project timeline to ensure seamless transitions between manufacturing stages.
During fermentation, upstream teams document harvest parameters in real time while downstream purification specialists engage during the final stages of cultivation to prepare for purifying the harvest.
This integration is supported by close collaboration across scientific, manufacturing and quality functions. The same cross-functional collaboration allows potential manufacturing issues to be addressed collectively before they become downstream execution risks. The company’s focused mid-sized structure enables direct communication and short decision-making pathways, allowing rapid responses to project needs while maintaining strict GMP compliance.
Embedding Quality Throughout Manufacturing
Richter BioLogics embeds analytical development and quality control directly into ongoing manufacturing campaigns. Its multi-site GMP-certified laboratories support analytical development, in-process monitoring, troubleshooting, comparability studies, release testing and stability programs. This infrastructure enables parallel workstreams, helps manage peak analytical demand, maintains business continuity and allows teams to adapt quickly to evolving client and process requirements.
“Our clients are involved with our manufacturing team from the beginning. There are no translation errors, here are no surprises.”
L
In-process samples are evaluated against predefined acceptance criteria throughout manufacturing, providing real-time insight into process performance. Results are reviewed collaboratively by manufacturing and analytical teams, creating opportunities to address deviations before they impact final product quality.
This proactive quality strategy strengthens risk management while helping clients avoid costly delays associated with late-stage manufacturing issues or regulatory concerns. Identifying and addressing challenges early, Richter BioLogics enhances process consistency and product reliability.
Documentation, Traceability and Regulatory Confidence
With more than 35 years of operating GMP-compliant facilities, Richter BioLogics views GMP manufacturing as a quality and documentation discipline. Comprehensive documentation behind every batch ensures processes are legible to regulators, auditable by clients and reproducible across campaigns.
Its batch record practices are designed to ensure complete traceability across development and manufacturing. Each GMP batch is executed against a master batch record that captures critical process parameters, in-process results and process events, along with their investigation, assessment and resolution. It has supported clients through regulatory interactions with the EMA, FDA and other global agencies, where the quality of its documentation has been consistently recognized. Notably, Richter BioLogics completed an FDA inspection in 2026 with zero observations, reflecting the operational discipline applied to every batch record, system and quality decision.
This commitment extends beyond manufacturing operations to materials management as well. Raw materials are tested upon receipt, stored under controlled conditions and tracked through comprehensive inventory systems. Media preparation, buffer formulation and chromatography resin handling follow established procedures supported by detailed documentation, helping minimize risk and maintain process consistency throughout production.
Plasmid DNA Manufacturing for Next- Generation Therapies
The operational capabilities developed across Richter BioLogics‘ microbial manufacturing platform are increasingly being applied to plasmid DNA production. As pDNA plays an increasingly important role in next-generation vaccines and therapies, demand for GMP-grade material continues to outpace industry manufacturing capacity, making reliable supply a strategic priority for sponsors.
pDNA production is Richter BioLogics‘ established service supported by its proprietary highyield pART platform process, designed to be scalable, robust and future-ready. The manufacturing pathway is clearly structured. It begins with tightly controlled bacterial fermentation optimized for plasmid yield and quality. Using well-characterized host strains and defined media formulations, manufacturing teams carefully manage cultivation conditions to maximize performance.
Following fermentation, downstream processing employs multi-step chromatographic and filtration techniques to isolate the target supercoiled pDNA from host cell proteins, genomic DNA, endotoxins and unwanted pDNA isoforms.
Final release testing is conducted under GMP conditions using a comprehensive analytical panel that evaluates identity, purity, potency and safety attributes. Extensive analytical capabilities support the demanding quality requirements of pDNA and enable it to serve clients from early development through clinical manufacturing.
pDNA is currently supplied for several commercial and near-commercial products, reflecting the consistent quality and regulatory robustness its partners rely on. Working alongside clients, Richter BioLogics rapidly mobilized its microbial production, purification and analytical capabilities to keep programs on track without compromising quality. This highlights the dependable supply, trust and long-term partnerships that continue to define its client relationships.
Advancing Biologics Through Expertise and Client-Centricity
A compelling endorsement for Richter BioLogics‘ approach comes from the global pharma and biotech clients. They consistently highlight the quality and engagement of its project teams, describing the relationship as a true partnership over a manufacturing contract. It has supported programs requiring rapid optimization before GMP manufacturing, with its process development teams working alongside client scientists to troubleshoot fermentation performance, develop purification strategies under time pressure and deliver GMP-ready processes on schedule.
„Being customer-centric means placing our clients‘ product success at the heart of everything we do. We understand that choosing a CDMO is about finding a true partner, one that will carry the same sense of accountability for the program’s success that the client does,“ says Kamphausen.
As demand for GMP-grade microbial products continues to rise, the need for experienced manufacturing partners will only grow. Recognized as the Biopharmaceutical CDMO Manufacturer of the Year in Europe 2026, Richter BioLogics is meeting this demand through continued investment in capacity, scientific expertise and operational excellence. Its recent facility expansions, strong regulatory track record and integrated service model position it to support the next generation of biologics.
Dr. Thilo Kamphausen
Head of Business Development at Richter BioLogics
Quelle: Life Sciences Review Europe, https://www.lifesciencesrevieweurope.com/richter-biologics-2026